Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 4/20 | 0.40 |
| ▸ | ICAM1 | P05362 | 4/20 | 0.40 |
| ▸ | ITGAL | P20701 | 4/20 | 0.40 |
| ▸ | PDE7A | Q13946 | 5/20 | 0.38 |
| ▸ | PDE7B | Q9NP56 | 2/20 | 0.38 |
| ▸ | KIF11 | P52732 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6201264 | 0.77 | ITGB2 (0.45) | ITGB2ICAM1ITGALALDH1A1MAPT | |
| SCHEMBL7151451 | 0.76 | ITGB2 (0.46) | ITGB2ICAM1ITGALALDH1A1LMNA | |
| SCHEMBL27525353 | 0.76 | ITGB2 (0.46) | ITGB2ICAM1ITGALALDH1A1LMNA | |
| SCHEMBL5546389 | 0.74 | KIF11 (0.47) | KIF11ALDH1A1LMNASMN1; SMN2NPC1 | |
| SCHEMBL1575987 | 0.73 | KIF11 (0.44) | ITGB2ICAM1ITGALKIF11ALDH1A1 | |
| SCHEMBL7621281 | 0.73 | ITGAL (0.76) | ITGB2ICAM1ITGAL | |
| SCHEMBL6196866 | 0.73 | ITGAL (0.76) | ITGB2ICAM1ITGAL | |
| SCHEMBL6927314 | 0.72 | CYP2A6 (0.43) | ITGB2ICAM1ITGALPDE7AKIF11 | |
| SCHEMBL3158225 | 0.72 | ALDH1A1 (0.44) | PDE7APDE7BALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL29417742 | 0.71 | KIF11 (0.51) | KIF11ALDH1A1SMN1; SMN2RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6521619-B2 | Bind to the interaction-domain of integrin lfa-1 interrupting enothelial cell-leukocyte adhesion | ICOS CORPORATION | 2003-02-18 | — | — | US | disclosed |
| US-20020156314-A1 | Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents | ICOS CORPORATION | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156314-A1 | Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents | ICAM1, VCAM1, CD47 | ITGB2 120/4885ICAM1 1/4885ITGAL 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.